FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy

Background Fifty percent of patients with muscle–invasive bladder cancer (MI-BC) die from their disease and current chemotherapy treatment only marginally increases survival. Novel therapies targeting receptor tyrosine kinases or activated oncogenes may improve outcome. Hence, it is necessary to stratify patients based on mutations in relevant oncogenes. Patients with non-muscle-invasive bladder cancer (NMI-BC) have excellent survival, however two-thirds develop recurrences. Tumor specific mutations can be used to detect recurrences in urine assays, presenting a more patient-friendly diagnostic procedure than cystoscopy. Methodology/Principal Findings To address these issues, we developed a mutation assay for the simultaneous detection of 19 possible mutations in the HRAS, KRAS, and NRAS genes. With this assay and mutation assays for the FGFR3 and PIK3CA oncogenes, we screened primary bladder tumors of 257 patients and 184 recurrences from 54 patients. Additionally, in primary tumors p53 expression was obtained by immunohistochemistry. Of primary tumors 64% were mutant for FGFR3, 11% for RAS, 24% for PIK3CA, and 26% for p53. FGFR3 mutations were mutually exclusive with RAS mutations (p = 0.001) and co-occurred with PIK3CA mutations (p = 0.016). P53 overexpression was mutually exclusive with PIK3CA and FGFR3 mutations (p≤0.029). Mutations in the RAS and PIK3CA genes were not predictors for recurrence-free, progression-free and disease-specific survival. In patients presenting with NMI-BC grade 3 and MI-BC, 33 and 36% of the primary tumors were mutant. In patients with low-grade NMI-BC, 88% of the primary tumors carried a mutation and 88% of the recurrences were mutant. Conclusions/Significance The mutation assays present a companion diagnostic to define patients for targeted therapies. In addition, the assays are a potential biomarker to detect recurrences during surveillance. We showed that 88% of patients presenting with low-grade NMI-BC are eligible for such a follow-up. This may contribute to a reduction in the number of cystoscopical examinations.

[1]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[2]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[3]  Li Zhao,et al.  Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms , 2008, Proceedings of the National Academy of Sciences.

[4]  W. Zhong,et al.  CK20 and Ki-67 as significant prognostic factors in human bladder carcinoma , 2010, Clinical and Experimental Medicine.

[5]  K. Baggerly,et al.  Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. , 2008, The Journal of urology.

[6]  E. Steyerberg,et al.  Patients’ perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison , 2008, BJU international.

[7]  Y. Lotan,et al.  Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. , 2010, Urologic oncology.

[8]  K. Zieger,et al.  Long‐term follow‐up of noninvasive bladder tumours(stage Ta): recurrence and progression , 2000, BJU international.

[9]  J. Hancock,et al.  Ras Isoforms Vary in Their Ability to Activate Raf-1 and Phosphoinositide 3-Kinase* , 1998, The Journal of Biological Chemistry.

[10]  L. Sobin,et al.  Histological Typing of Urinary Bladder Tumours , 1999, International Histological Classification of Tumours.

[11]  K. Guan,et al.  Transformation Potential of Ras Isoforms Correlates with Activation of Phosphatidylinositol 3-Kinase but Not ERK* , 2004, Journal of Biological Chemistry.

[12]  Y. Samuels,et al.  Oncogenic PI3K and its role in cancer , 2006, Current opinion in oncology.

[13]  Carl W. Miller,et al.  Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. , 2007, Leukemia research.

[14]  S. Trudel,et al.  Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma , 2004, British journal of haematology.

[15]  N. Malats,et al.  PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. , 2006, Cancer research.

[16]  E. Zwarthoff,et al.  Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes , 2010, PloS one.

[17]  W. Gregory,et al.  Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer , 2009, Clinical Cancer Research.

[18]  D. McConkey,et al.  Targeting EGFR in bladder cancer. , 2007, World journal of urology.

[19]  Adel H Jebar,et al.  FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma , 2005, Oncogene.

[20]  Hester F. Lingsma,et al.  Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle–Invasive Bladder Cancer , 2010, Clinical Cancer Research.

[21]  Francesca Molinari,et al.  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.

[22]  K. Nakao,et al.  Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway , 2004, Nature Medicine.

[23]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. , 2008, European urology.

[24]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[25]  Peter Kraft,et al.  PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Inazawa,et al.  PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma , 2006, Cancer science.

[27]  A. Bardelli,et al.  Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer , 2009, Journal of the National Cancer Institute.

[28]  T. H. van der Kwast,et al.  Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  G. Rewcastle,et al.  Functional differences between two classes of oncogenic mutation in the PIK3CA gene. , 2009, Biochemical and biophysical research communications.

[30]  Phillip T. Hawkins,et al.  Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ , 2000, Cell.

[31]  Anirban P. Mitra,et al.  Molecular pathogenesis and diagnostics of bladder cancer. , 2009, Annual review of pathology.

[32]  C. Dinney,et al.  Targeted therapies in bladder cancer--an update. , 2007, Urologic oncology.

[33]  N. Caraway,et al.  A review on the current state of urine cytology emphasizing the role of fluorescence in situ hybridization as an adjunct to diagnosis , 2010, Cancer cytopathology.

[34]  Dieter Jocham,et al.  Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. , 2005, The Journal of urology.

[35]  M. Göke,et al.  Signal Transduction Pathway of Human Fibroblast Growth Factor Receptor 3 , 1997, The Journal of Biological Chemistry.

[36]  M. Knowles,et al.  Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer , 2009, Cancer and Metastasis Reviews.

[37]  W. Kassouf,et al.  Biomarkers for detection and surveillance of bladder cancer. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[38]  S. Santa Cruz,et al.  Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  F. Real,et al.  Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern , 2007, Proceedings of the National Academy of Sciences.

[40]  T. H. van der Kwast,et al.  Molecular evolution of multiple recurrent cancers of the bladder. , 2000, Human molecular genetics.

[41]  C. Cordon-Cardo,et al.  Prognostic significance of p27Kip1 expression in bladder cancer , 2007, BJU international.

[42]  P. Hawkins,et al.  Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. , 2000, Cell.

[43]  T. H. van der Kwast,et al.  FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma , 2004, Cancer Research.

[44]  M. Knowles,et al.  Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer , 2007, Oncogene.

[45]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[46]  A. El‐Naggar,et al.  Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. , 2008, The Journal of clinical endocrinology and metabolism.

[47]  O. Beahrs.  The American Joint Committee on Cancer. , 1984, Bulletin of the American College of Surgeons.

[48]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[49]  Unyime Nseyo,et al.  A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. , 2007, The Journal of urology.

[50]  L. Kessler,et al.  Medicare Payments from Diagnosis to Death for Elderly Cancer Patients by Stage at Diagnosis , 1995, Medical care.

[51]  M. Knowles,et al.  FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer , 2007, The Journal of pathology.

[52]  S. Anai,et al.  1-tert-Butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a Selective Tyrosine Kinase Inhibitor of Fibroblast Growth Factor Receptor-3 (FGFR3), Inhibits Cell Proliferation of Bladder Cancer Carrying the FGFR3 Gene Mutation along with Up-Regu , 2010, Journal of Pharmacology and Experimental Therapeutics.

[53]  F. Hamdy,et al.  FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. , 2009, European urology.

[54]  M. Hayman,et al.  The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3 , 2003, Oncogene.

[55]  Marc-André Elsliger,et al.  Rare cancer-specific mutations in PIK3CA show gain of function , 2007, Proceedings of the National Academy of Sciences.

[56]  Michael J. Fry,et al.  Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.

[57]  D. Neal,et al.  Epidermal growth factor receptor and bladder cancer: a review. , 1992, Urologia internationalis.

[58]  E. Zwarthoff,et al.  Bladder cancer biomarkers and their role in surveillance and screening , 2009, International journal of urology : official journal of the Japanese Urological Association.

[59]  Liana Adam,et al.  Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. , 2005, Cancer research.

[60]  Alberto Redaelli,et al.  The health economics of bladder cancer: a comprehensive review of the published literature. , 2003, PharmacoEconomics.

[61]  W. Schulz,et al.  Understanding urothelial carcinoma through cancer pathways , 2006, International journal of cancer.

[62]  E. Zwarthoff.  Detection of tumours of the urinary tract in voided urine , 2008, Scandinavian journal of urology and nephrology. Supplementum.

[63]  J. Downward,et al.  Ras and Phosphoinositide 3-Kinase: Partners in Development and Tumorigenesis , 2007, Cell cycle.

[64]  P. L. Bergsagel,et al.  MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. , 2006, Blood.

[65]  D. Theodorescu,et al.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC) , 2010, Expert Reviews in Molecular Medicine.

[66]  L. Sobin,et al.  TNM classification of malignant tumors, fifth edition (1997) , 1997, Cancer.

[67]  Henry Z. Montes,et al.  TNM Classification of Malignant Tumors, 7th edition , 2010 .

[68]  M. Landthaler,et al.  FGFR3 and PIK3CA mutations are involved in the molecular pathogenesis of solar lentigo , 2009, The British journal of dermatology.

[69]  T. H. van der Kwast,et al.  The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour , 2009, The Journal of pathology.

[70]  E. Zwarthoff,et al.  A Simple and Fast Method for the Simultaneous Detection of Nine Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer and Voided Urine , 2005, Clinical Cancer Research.

[71]  E. Zwarthoff,et al.  A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene , 2009, BMC Research Notes.

[72]  S C Robertson,et al.  Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. , 2001, Molecular biology of the cell.

[73]  Y. Ding-wei,et al.  Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors , 2004, Urological Research.

[74]  B. Vogelstein,et al.  Clonal origin of bladder cancer. , 1992, The New England journal of medicine.

[75]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[76]  K. Hemminki,et al.  Allelic losses demonstrate monoclonality of multifocal bladder tumors , 2000, International journal of cancer.

[77]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[78]  J. Zheng,et al.  Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors. , 1993, Urological research.

[79]  L. Kiemeney,et al.  The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. , 1993, British Journal of Cancer.

[80]  C. Abbou,et al.  Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. , 2001, The American journal of pathology.

[81]  M. Rosenblum,et al.  Antitumor activity of fibroblast growth factor receptor 3–specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis , 2008, Molecular Cancer Therapeutics.

[82]  Anirban P. Mitra,et al.  Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. , 2010, European urology.

[83]  W. Sellers,et al.  PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. , 2009, Cancer research.

[84]  L. Kiemeney,et al.  Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis. , 2000, Urology.

[85]  H. Wallerand,et al.  FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. , 2003, Cancer research.

[86]  M. Knowles,et al.  Mutant Fibroblast Growth Factor Receptor 3 Induces Intracellular Signaling and Cellular Transformation in a Cell Type- and Mutation-Specific Manner , 2009, Oncogene.

[87]  Y. Ceylan,et al.  Evaluation of Pain Caused by Urethrocystoscopy in Patients with Superficial Bladder Cancer: A Perspective of Quality of Life , 2005, Oncology Research and Treatment.